top of page

Women's Health

Breast Lesion Tracking

Epidemiology & Progression:

Breast cancer is the most common cancer in women worldwide [1]. Incidental or screen-detected breast lesions are common. Management is guided by imaging features using the ACR BI-RADS® lexicon, which categorizes findings from 0 (Incomplete) to 6 (Known Malignancy) [ACR BI-RADS®]. BI-RADS 4 (Suspicious) and 5 (Highly Suggestive of Malignancy) lesions warrant biopsy, with malignancy rates of ~20-50% and >95% respectively [ACR BI-RADS®]. Progression varies widely by cancer subtype.

Clinical Value:

Systematic tracking using BI-RADS® ensures appropriate follow-up recommendations (e.g., short-interval follow-up for BI-RADS 3, biopsy for BI-RADS 4/5) are communicated and completed [ACR BI-RADS®]. This facilitates early detection of breast cancer when it is most treatable, improving survival rates. Failure to track BI-RADS recommendations is a significant patient safety concern and source of litigation [45].

Return on Investment (ROI):

Guideline-adherent breast lesion management drives appropriate use of diagnostic mammography, ultrasound, MRI, biopsies, and surgical/oncology referrals. Based on proprietary modeling for a medium-sized hospital system, Thynk Health's tracking can capture an estimated $3.5 million in additional net revenue over five years (70% vs 30% capture) through timely diagnostics and retained cancer care pathways [Thynk Health ROI Data, 2025].

Feature List:

  • Tracks ER mentions of incidental Breast Findings 

  • BI-RADS® Integration: Automatically tracks BI-RADS categories based on NLP extraction from mammography, US, or MRI reports. 

  • Guideline-Based Follow-up Scheduling: Creates tasks for short-interval follow-up (BI-RADS 3) or biopsy recommendations (BI-RADS 4/5). 

  • Biopsy Result Tracking & Correlation: Links biopsy pathology results back to the imaging finding. 

  • Surgical/Oncology Referral Workflow: Triggers referrals based on BI-RADS category or biopsy results. 

Ovarian Cysts

Epidemiology & Progression:

Ovarian cysts are extremely common, especially in premenopausal women. Most are benign functional cysts that resolve spontaneously. Incidental cysts found on imaging in postmenopausal women or complex-appearing cysts require evaluation based on imaging features (size, septations, solid components) and patient age/risk factors [ACR White Paper Ovary, 46]. While ovarian cancer is less common, it has high mortality due to often late diagnosis; certain complex cysts carry malignancy risk [46].

Clinical Value:

Tracking ovarian cysts according to ACR guidelines allows differentiation between likely benign lesions needing no/minimal follow-up and potentially suspicious cysts requiring further imaging (ultrasound, MRI) or gynecologic/oncology referral [46]. This ensures timely diagnosis of ovarian cancer while avoiding unnecessary anxiety and intervention for benign cysts. Failure to track suspicious findings risks delayed cancer diagnosis [47].

Return on Investment (ROI):

Appropriate management involves follow-up ultrasound/MRI, GYN consults, and potential surgery (oophorectomy). Based on proprietary modeling for a medium-sized hospital system, Thynk Health's tracking of ovarian findings (predominantly cysts/masses) can capture an estimated $0.5 million in additional net revenue over five years (70% vs 30% capture) through appropriate imaging surveillance and surgical interventions [Thynk Health ROI Data, 2025].

Feature List:

  • ACR Guideline Integration (Adnexal Lesions): Applies logic based on cyst size, complexity features (septations, solid components), and patient menopausal status. 

  • Follow-up Ultrasound/MRI Scheduling: Manages surveillance imaging based on guidelines. 

  • GYN/Oncology Referral Workflow: Triggers referrals for complex or enlarging cysts, especially in postmenopausal women. 

Fibroid Tracker

Epidemiology & Progression:

Uterine fibroids (leiomyomas) are the most common pelvic tumor in women, affecting up to 70-80% by age 50, particularly prevalent in Black women [48]. They are benign smooth muscle tumors. While often asymptomatic, they can cause significant symptoms (heavy bleeding, pain, infertility) depending on size, number, and location. Progression involves potential growth, degeneration, or increasing symptom burden over time [48]. Malignant transformation (leiomyosarcoma) is extremely rare (<0.1%).

Clinical Value:

Tracking fibroid size, location, and associated symptoms helps guide management decisions, ranging from watchful waiting to medical therapy (hormones, GnRH agonists) or interventions (uterine artery embolization, myomectomy, hysterectomy) [ACOG Practice Bulletin Fibroids]. Monitoring growth and symptom correlation ensures timely and appropriate intervention when needed. Untracked symptomatic fibroids can lead to chronic anemia, pain, and reduced quality of life.

Return on Investment (ROI):

Management involves pelvic imaging (US, MRI), GYN consultations, medical therapies, and high-value procedures (UAE, myomectomy, hysterectomy). No direct ROI data is provided in memory. However, systematic tracking identifies symptomatic patients and monitors growth, ensuring appropriate referrals are made and retained within the system. This likely generates  for a medium system through imaging, consultations, and procedural interventions [Educated Estimate based on Prevalence/Procedure Costs, ACOG].

Feature List:

  • NLP for Fibroid Size/Location (Potential): Could extract key details about fibroid burden from US/MRI reports. 

  • Symptom Correlation (Potential Integration): Linking imaging to documented symptoms (e.g., bleeding, pain) in the EHR. 

  • GYN Referral Workflow: Facilitates referrals for symptomatic patients or those with significant fibroid burden/growth. 

  • Procedure Pathway Tracking (Potential): Could track patients undergoing specific treatments like UAE or myomectomy. 

Important Note on ROI: The Return on Investment (ROI) figures presented are derived from Thynk Health's proprietary performance data analysis. These calculations are based on models simulating a medium-sized hospital system processing approximately 600,000 CT scans annually through emergency departments and utilizing multispecialty guidelines for follow-up care pathways and associated downstream revenue capture. Actual ROI may vary based on specific institutional factors, patient populations, and payer mix.  

References: 

[1] GLOBOCAN 2020 / Cancer.org 
[45] Sickles, E. A., et al. (2013). ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA, American College of Radiology. 
[46] Levine, D., et al. (2010). Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology. / Patel, M. D., et al. (2018). ACR Appropriateness Criteria® Clinically Suspected Adnexal Mass. Journal of the American College of Radiology. 
[47] American College of Obstetricians and Gynecologists. (2016). Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstetrics & Gynecology. 
[48] Stewart, E. A., et al. (2017). Epidemiology of uterine fibroids: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology. 

bottom of page